OncoMatch/Clinical Trials/NCT07219576
Retifanlimab and Ruxolitinib In Solid Malignancies
Is NCT07219576 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Ruxolitinib and Retifanlimab for non small cell lung carcinoma.
Treatment: Ruxolitinib · Retifanlimab — The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
having progressed on prior PD-1/PD-L1 therapy (radiographic progression within 6 months of discontinuing immunotherapy; immunotherapy does not need to be the immediate line of preceding therapy)
Cannot have received: Janus kinase inhibitor
No prior treatment with Janus kinase inhibitors
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0×10^9/L; Platelet count ≥ 100×10^9/L; Hemoglobin level ≥ 8.5 g/dL; criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks
Kidney function
Serum creatinine ≤ 2 mg/dL (or estimated creatinine clearance ≥ 30 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas)
Liver function
Aspartate Aminotransferase and Alanine Aminotransferase ≤ 2.5 x upper limit of normal; Bilirubin ≤1.5 x upper limit of normal
Adequate organ and marrow function: * Absolute neutrophil count ≥ 1.0×10^9/L. * Platelet count ≥ 100×10^9/L. * Hemoglobin level ≥ 8.5 g/dL; criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks. * Serum creatinine ≤ 2 mg/dL (or estimated creatinine clearance ≥ 30 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas). * Aspartate Aminotransferase and Alanine Aminotransferase ≤ 2.5 x upper limit of normal. * Bilirubin ≤1.5 x upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Diego Moores Cancer Center · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify